231 related articles for article (PubMed ID: 33507500)
21. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
[TBL] [Abstract][Full Text] [Related]
24. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
Liu SC; Lee CC; Chuang SM; Sun FJ; Zeng YH
Diabetes Metab; 2021 May; 47(3):101184. PubMed ID: 32827752
[TBL] [Abstract][Full Text] [Related]
25. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Diabetes Obes Metab; 2015 Feb; 17(2):136-44. PubMed ID: 25298165
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
Kadowaki T; Muto S; Ouchi Y; Shimazaki R; Seino Y
Expert Opin Pharmacother; 2017 Dec; 18(18):1903-1919. PubMed ID: 28901796
[TBL] [Abstract][Full Text] [Related]
27. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
[TBL] [Abstract][Full Text] [Related]
28. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Huisman H; Jones R; von Eynatten M; Patel S; Woerle HJ
Lancet; 2013 Oct; 382(9902):1413-23. PubMed ID: 23948125
[TBL] [Abstract][Full Text] [Related]
29. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
[TBL] [Abstract][Full Text] [Related]
31. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
32. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Parthan G; Bhansali S; Kurpad AV; Walia R; Bhat K; Bhansali A
BMC Pharmacol Toxicol; 2018 Jul; 19(1):38. PubMed ID: 29970184
[TBL] [Abstract][Full Text] [Related]
33. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
Forst T; Uhlig-Laske B; Ring A; Ritzhaupt A; Graefe-Mody U; Dugi KA
Diabetes Obes Metab; 2011 Jun; 13(6):542-50. PubMed ID: 21352464
[TBL] [Abstract][Full Text] [Related]
34. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
35. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
36. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.
Seino Y; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
Curr Med Res Opin; 2018 Jun; 34(6):981-994. PubMed ID: 29448833
[TBL] [Abstract][Full Text] [Related]
38. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Bajaj M; Gilman R; Patel S; Kempthorne-Rawson J; Lewis-D'Agostino D; Woerle HJ
Diabet Med; 2014 Dec; 31(12):1505-14. PubMed ID: 24824197
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
Zeng Z; Choi DS; Mohan V; Emser A; Siddiqui K; Gong Y; Patel S; Woerle HJ
Curr Med Res Opin; 2015 Jan; 31(1):99-106. PubMed ID: 25215428
[TBL] [Abstract][Full Text] [Related]
40. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial.
Vellanki P; Rasouli N; Baldwin D; Alexanian S; Anzola I; Urrutia M; Cardona S; Peng L; Pasquel FJ; Umpierrez GE;
Diabetes Obes Metab; 2019 Apr; 21(4):837-843. PubMed ID: 30456796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]